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     Manuscript 
 
Abstract 
Osteoclasts are components of HSC niches, but their role as contributors to the HSC 
homeostasis and release are still controversial. We aimed to investigate whether an 
acute blood loss of 10% of total blood content, and the consequent intense 
hematopoiesis would affect osteoclast differentiation and activity. Isolated peripheral 
blood (PBL), spleen, and bone marrow (BM) cells from bones of hind limbs were 
investigated for the presence of specific subpopulations of osteoclast precursors – 
B220-CD3-NK1.1-CD11b-/lowCD115+CD117+ cells in BM, and B220-CD3-NK1.1-Gr-1-
CD11b+CD115+ cells in PBL and spleen, as well as the RANK+ cycle-arrested quiescent 
osteoclast precursors (QOPs). Expression of osteoclastogenesis-related genes: 
CD115, RANK, and cathepsin K, and the potential of BM cells to form osteoclast-like 
cells in vitro and their activity in vivo were also evaluated. We observed an increase in 
spleen cellularity and myelopoiesis during 1 week following blood loss, without any 
significant effects on BM cellularity or BM myeloid precursors including cells with high 
osteoclastogenic potential. However, at 1 week post-bleeding, hematopoiesis 
significantly promoted the expression of cathepsin K, IL-34, and BMP-6. QOPs 
increased significantly in spleen 2 days following bleeding, while osteoclast activity 
remained unchanged up to 2 weeks post-bleeding. Osteoclast-dependent B-cell 
differentiation was affected at the pre-B stage of maturation in BM, while the LSK 
population expanded in BM and spleen after 2 days post-bleeding. Our data 
demonstrate that an acute blood loss promotes differentiation and maturation of 
osteoclasts at 1 week, but does not enhance osteoresorption in vivo up to 2 weeks of 
the recovery period, and identifies osteoclast differentiation as a consequent and 
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important event in establishing HSCs homeostasis following hematopoietic stress.   
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     Introduction 
 
 
Mature blood cells originate in the bone marrow (BM) by proliferation and differentiation 
of hematopoietic stem cells (HSCs) within distinct hematopoietic niches, local 
microenvironments within the BM tissue, which are defined by both their anatomy and 
function [1]. Fine tuning of the processes within the niches, as well as mechanisms of 
HSC regulation, such as quiescence or mobilization from BM to the circulation [2] 
involve activities and interactions of different cell types [3] – endothelial cells, CXCL12-
abundant reticular cells (CAR) [4] and a discrete population of tissue resident 
macrophages – osteomacs [5]. Various cells at the endosteal surface of trabecular 
bone – osteoblasts of mesenchymal and osteoclasts of hematopoietic origin, physically 
support HSCs and provide signals that control their fate [2,6–16].  
Osteoclasts, bone resorbing cells, differentiate from myeloid progenitors, due to a 
variety of factors, most notably macrophage colony-stimulating factor (M-CSF) and 
receptor activator of nuclear factor kappa-B ligand (RANKL) [17]. These ligands bind to 
corresponding receptors c-Fms/CD115 (M-CSF receptor) and RANK (RANKL receptor) 
[17] expressed on osteoclast precursors, and the BM microenvironment is highly 
supportive of osteoclastogenesis [18]. Recently, several distinct osteoclast precursor 
subpopulations have been identified – B220-CD3-NK1.1-CD11b-/lowCD115+CD117+ cells 
by Jacquin et al. [19] in the BM, and B220-CD3-NK1.1-CD11b+Ly6ChiCD115+Ly6G-
CD117int by Jacome-Galarza et al. [20] in the spleen and peripheral blood – both with a 
4 
 
very high potential to generate osteoclasts in vitro. Muto A et al. [21] have identified a 
population of RANK+ cycle-arrested quiescent osteoclast precursors (QOPs) that 
circulate in blood and reach the bone. Their lifespan is between 6-8 weeks [22], while 
Interleukin (IL)-34, a newly discovered alternative ligand for CD115 produced by 
vascular endothelial cells, helps in their maintenance [23], especially in the spleen. 
The exact role and mechanisms of mature osteoclasts as contributors to the HSC 
release from the niches are somewhat controversial. For the most part it seems they 
ease the release of HSCs into circulation [2,24–27] by secreting enzymes which 
mediate the cleavage of CXCL12/SDF-1 and other molecules responsible for the 
anchorage of HSCs in the niche. It has been shown that the inhibition of osteoclast 
function reduces the number of BM HSCs in vivo [28,29] and increases the number of 
HSCs in the spleen [30]. Others have, however, reported that osteoclasts are either 
dispensable for HSC maintenance and mobilization [31–33], or that they affect the HSC 
niche only indirectly, through an effect on osteoblast differentiation [25], while at the 
same time actively modulating B-cell development [34]. Taken together, this indicates 
that osteoclasts are important for the homeostasis of the BM microenvironment.  
BM is not the only site for hematopoiesis in mice, resulting from development and 
trafficking of HSCs in non-marrow tissues during embryogenesis. Shortly before birth 
HSC migrate from the fetal liver to the BM, while the number of hematopoietic 
progenitors in the spleen increases. This establishes the spleen as a hematopoietic 
organ in adult mice, albeit at low levels [35], because the spleen contains very few 
primitive long-term reconstituting HSCs [36,37]. Its microenvironment supports 
development of erythroid cells [38], later stages of myeloid and dendritic cells, as well 
as BM-derived monocyte precursors [39], but, in physiological conditions, it is not 
conducive to osteoclastogenesis [40,41]. After an hematological stress in adult mice, 
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both BM and spleen niches are activated and stimulate HSC proliferation [22] to 
maintain the RBC count and oxygenation homeostasis [42]. The main regulator of RBC 
production is erythropoietin (Epo), produced mostly by kidneys, which serves as a good 
estimator of the extent of erythropoietic activity [43]. 
Since the effects of enhanced hematopoiesis on proliferation and differentiation of 
discrete osteoclast precursor subpopulations and osteoclast activity have not been fully 
elucidated, we hypothesized that the intense hematopoiesis following blood loss would 
also affect cells of the osteoclast lineage. To test this hypothesis, we subjected mice to 
an acute blood loss (10% of total blood volume) and monitored the indicators of 
hematopoietic homeostasis by determining the changes in populations of Lin-Sca1+c-
kit+cells, macrophages, and B-cell precursors, at the same time assessing the 
phenotype of discrete osteoclast precursors at several time points within the first follow-
up week, and the activity up to 2 weeks following blood loss.  
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     Materials and Methods  
 
Mouse model of acute blood loss 
All experiments were performed on female 10-12 week-old C57BL/6 mice. The animals 
were housed at the Animal Care Unit of the Institute for Brain Research, Zagreb. 
Maintenance of animals and all experimental procedures strictly followed the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. All animal 
protocols were approved by the Ethics Committee of the University of Zagreb School of 
Medicine (Zagreb, Croatia). Animals were randomly distributed into six groups (control 
and bled groups – each group was bled only once at 12h, 24h, 48h, 72h or 1 week 
before sampling, n=3). The experiments were repeated at least three times. Mice were 
weighed to determine their approximate total blood content and then anesthetized with 
3-bromoethanol (Sigma-Aldrich, Milwaukee, MI, USA) i.p. according to the 
manufacturer’s instructions. The bleeding was performed by introducing a capillary 
glass tube (Lancer, Brunswick company, USA) at the medial canthus of the orbit to 
access the retro-orbital plexus [44], and 10% of the calculated blood volume was 
drawn. Mice were given appropriate fluid replacement. Samples for blood analysis were 
collected into BD microtainer K2E tubes containing EDTA. The number of reticulocytes 
and red blood cells were measured using the Sysmex XT-2000i Automated 
Hematology Analyzer (Sysmex America Inc., Lincolnshire, IL, USA). 
 
In vitro cell culture 
BM cells for osteoclast-like (OCL) cell differentiation were flushed out from femoral and 
tibial medullar cavities and prepared as previously described [45,46]. Non-adherent 
cells were harvested and plated into 96-well plates at a density of 0.18×106/well in 0.2 
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mL/well of α-MEM/10% FBS supplemented with 20 ng/mL (rm)M-CSF and 30 ng/mL 
rmRANKL (R&D Systems). At day 3 following plating cells were fixed and OCLs were 
identified by staining with a commercially available kit (Sigma-Aldrich), as tartrate-
resistant acid phosphatase (TRAP)-positive multinucleated cells. Using light 
microscopy, cells with three or more nuclei were counted as OCL [45].  
 
Flow cytometry  
Isolated BM, spleen and peripheral blood cells were stained using commercially 
available anti-mouse lineage mixture kit (Alexa fluor 488 conjugated anti-CD3, anti-
CD11b, anti-CD45R, anti-Ly6C/G and anti-TER119) (Invitrogen, Invitrogen corporation, 
CA, USA) in combination with PE-conjugated anti-Sca-1 and APC-conjugated anti-c-kit 
for identification of primitive HSCs. Identification of osteoclast progenitors was 
performed by using FITC-conjugated anti-mouse CD45R, CD3 and NK1.1; anti-mouse 
CD115-biotin conjugated in combination with streptavidin-PE conjugate, anti-mouse 
CD11b-Pe-Cy7 and anti-mouse CD117-APC or anti-mouse Gr-1 APC, also anti-mouse 
CD115-biotin in combination with streptavidin-FITC conjugate and anti-mouse RANK-
PE antibodies. Anti-mouse-F4/80 PE and anti-mouse CD11b-Cy-7 were used for 
identification of monocyte/macrophage precursors. As an erythroid cell marker, anti-
mouse-TER119 PE was used. Identification of B-cell precursors at different stages of 
development was performed by using anti-mouse IgM-FITC, anti-mouse CD43 PE, 
anti-mouse CD19 PeCy-7 and anti-mouse B220-APC. Unless otherwise indicated, the 
antibodies were purchased from eBioscience (Affymetrix, San Diego, CA, USA). Cells 
were analyzed for immunophenotypical enumeration of several specific cell 
populations, using dual laser FACSCalibur II (Beckton Dickinson, San Jose, CA, SAD) 
and CellQuest software (Becton Dickinson Immunocytometry Systems). 
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Gene expression analysis 
Total RNA was extracted from isolated BM, spleen and homogenized bones (tibia) 
using TRI reagent (Applied Biosystems, Foster City, CA, USA) and reversely 
transcribed (1µg) to cDNA and amplified (20 ng/well) by quantitative (q)PCR using an 
ABI Prism 7500 Sequence detection system (Applied Biosystems) in a 25µL reaction 
volume [46]. Commercially available TaqMan Gene Expression Assays for osteoclast-
specific genes: cFms (Csf1r; Mm00432689_m1), RANK (Tnfrs11a; Mm00437135_m1), 
and catepsinK (CtsK; Mm00484039_m1); and osteoblast-specific genes: runt-related 
transcription factor (Runx2; Mm00501580_m1), osterix (Osx, Sp7, Mm00504574_m1), 
osteocalcin (OC, Bglap1; Mm03413826_m1), bone-sialoprotein(BSP, Ibsp, 
Mm00492555_m1), CXCL12/SDF-1 (Sdf1 Mm00445553_m1), and bone 
morphogenetic protein (BMP)-6 (Mm01332882_m1); as well as IL-34 
(Mm01243248_m1) were purchased from Applied Biosystems. The following primers 
for β-actin were used, forward: CAT TGC TGA CAG GAT GCA GAA, reverse: GCT GAT 
CCA CAT CTG CTG GA. Comparative quantification algorithms ∆∆Ct, 2-∆∆Ct formula, 
was used to express fold differences of the gene expression. Ct for the gene of interest 
in the test sample and the calibrator sample (control) were adjusted in relation to β-
actin (housekeeping gene). Data are expressed as mean± standard deviation (SD)  of 
the representative experiment, and SD values present variability between the technical 
replicates within a single experiment. The methodological studies of quantitative PCR 
analysis suggest that the least difference in gene expression that could be reproducibly 
detected is around 100% [46,47] and therefore we assume that a difference of 100% or 
more in gene expression, repeating through all experiments, is biologically significant. 
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     Enzyme-linked immunosorbent assay (ELISA) 
Blood samples, 500µL per mouse, were allowed to clot for 3 hours at room temperature 
before centrifuging for 20 min. at 2000 g. The serum was removed and stored at -20°C. 
Concentrations of serum erythropoietin (Epo) and mouse cross-linked C-telopeptide of 
type I collagen (CTX-I) were determined using commercially available ELISA kits 
(Quantikine Immunoassay, R&D systems, Minneapolis, MN, USA and Cusabio Biotech 
Co., Ltd., China, respectively) according to the manufacturers’ directions.   
Histology and Histomorphometry  
Serial sections of mouse femora were prepared and stained for tartrate-resistant acid 
phosphatase (TRAP) activity as previously described [47]. Osteoclasts were identified 
as red multinucleated cells adjacent to the bone surface, and were counted in the whole 
diaphyseal areas, 1 mm distant from the epiphyseal plate. The total number of 
osteoclasts was normalized to the measured bone perimeter and expressed as the 
number of osteoclasts per millimeter of bone perimeter.  
Statistical analysis 
All experiments were performed at least three times. Numerical data for blood 
parameters (reticulocytes, erythrocytes and serum Epo levels), gene expression 
analysis and cell culture are expressed as mean±standard deviation (SD). Statistical 
analysis of the group difference, each time point versus control, was performed by 
unpaired two-tailed Student's test with Bonferroni correction for multiple testing giving 
the significance at p≤0.01 (calculated for α=0.05 and total number of five comparisons 
– for each of the five experimental groups vs control). Statistical analyses were 
performed using MedCalc for Windows, version 13.0 (MedCalc Software, Ostend, 
Belgium).  
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Results: 
Reduction by 10% of total blood volume significantly stimulates murine 
erythropoiesis 
Mice were subjected to an acute blood loss of 10% of total blood volume estimated per 
mouse weight, at several time points up to one week, and erythropoietic parameters 
were assessed. The number of reticulocytes increased in peripheral blood (PBL) 
samples reaching significant difference at 1 week following bleeding compared to 
control (p≤0.01) (Fig. 1a). In parallel, the number of erythrocytes slightly decreased, 
with full recovery at 1 week (Fig. 1a). To further confirm the induction of erythropoiesis, 
we measured the concentration of serum Epo and found that it was significantly 
increased at 24h of the recovery period (p≤0.01) (Fig. 1b). Flow-cytometric analysis of 
BM cells showed an approximately 1.4 fold increase of absolute number of TER119+ 
erythroblasts, nucleated erythrocyte precursors, starting at day 3, and reaching 
significant difference at day 7 post-bleeding (p≤0.01) (Fig. 1c). Moreover, there was a 
5-fold increase in the absolute number of TER119+ cells in the spleen at day 3, with 
significant difference at day 7 post-bleeding compared to control (p≤0.01) (Fig. 1c). 
 
Enhanced hematopoiesis expands murine LSK cells and alters the number of 
macrophages 
To determine the changes of specific cell populations within BM and spleen 
microenvironment, we performed flow-cytometric analysis of BM, spleen and PBL 
samples. We observed no perceptible changes of total BM cellularity, while there was 
an increase of total spleen cellularity in the follow-up period (Fig. 2a). In parallel, 
primitive hematopoietic cells, the Lin-Sca-1+c-kit+ (LSK) population, expanded 
significantly by approximately 1.5 fold in BM at 48h to 72h compared to control 
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(p≤0.01). In spleen, the expansion of the LSK population started at 24h by 2.5 fold and 
significantly peaked at 1 week following blood loss (p≤0.01) (Fig. 2b). Enhanced 
erythropoiesis affected the monocyte population, observed as an average 1.4 fold 
increase of F4/80+CD11b+ cells at 1 week post-bleeding in spleen and approximately 
1.8 fold reduction in PBL starting at day 1, without significant changes in BM (Fig. 2c).  
 
Blood loss modifies the number of murine osteoclast precursors and B-lymphoid 
cells 
We assessed the effects of blood loss on distinct subpopulations of osteoclast 
precursors in BM, spleen and PBL. There were no perceptible effects on the osteoclast 
precursor population (B220-CD3-NK1.1-CD11b-/lowCD115+CD117+) in BM, (Fig. 3a), 
spleen and PBL (B220-CD3-NK1.1-Gr-1-CD11b+CD115+) (Fig. 3a). We found that the 
number of QOPs (CD11b-Gr-1-RANKhighCD115low) in spleen and PBL were increased 
during the entire follow-up period, reaching significant difference at days 2 to 7 in 
spleen, while it increased only transiently in the BM (Fig. 3b).  
Given the close association between B-lymphoid and osteoclast lineages [34,48,49], 
we also monitored the populations of B-cell precursors following blood loss. The 
number of pre-proB cells (B220+IgM-CD43+CD19-) in spleen showed a small increase 
during the post-bleeding period, with no changes in BM (Fig. 4a). The pro-B cell 
(B220+IgM-CD43+CD19+) population in BM was reduced after 48h, with a transient 
increase in spleen (Fig. 4b). Finally, the population of pre-B (B220+IgM-CD43-CD19+) 
cells was significantly reduced in BM at days 3 to 7 following blood loss (p≤0.01), with 
transient changes in spleen (Fig. 4c). The population sizes in PBL for all evaluated B-
cell precursors were discrete, and no perceptible changes were observed (data not 
shown). 
12 
 
 
Alteration of osteoclast and osteoblast specific markers in murine BM following 
blood loss 
To assess the markers of osteoclast differentiation and maturation, we investigated the 
expression of osteoclast-specific genes: CD115, RANK and CtsK, and the expression 
of IL-34. Only the expression of CtsK, an enzyme abundantly expressed in mature 
osteoclasts, was highly up-regulated toward the follow-up end point (Fig. 5a). The 
expression of IL-34 was transiently down-regulated at 24h but then highly up-regulated 
at 1 week following blood loss (Fig. 5a).  
As the function and maturation of osteoclasts and osteoblasts is tightly coupled, we 
also evaluated the expression of osteoblast-specific genes: Runx2, Osx, BSP, OC and 
the expression of BMP-6. The expression pattern for Runx2 showed no changes 
throughout the evaluated period, while the most obvious up-regulation was observed 
for Osx (a transcription factor essential for osteoblast differentiation), although BSP, OC 
(markers of mature osteoblasts) and BMP-6 (an osteoinductive cytokine) followed a 
similar pattern (Fig. 5b). 
 
Blood loss alters the osteoclastogenic potential of murine BM cells in vitro  
To assess the osteoclastic differentiation potential of bone marrow cells after an acute 
blood loss, we cultured BM cells in osteclastogenic conditions. The total number of 
TRAP+ cells (≥ 3 nuclei/cell) was significantly lower (p≤0.01) at 24h and 1 week of the 
post-bleeding period compared with the control (Fig 6a), but the osteoclasts were 
larger and contained significantly (p≤0.01) more nuclei/osteoclast (Fig 6b). For in vivo 
evaluation of the osteoclast number and activity, we measured serum levels of mouse 
cross-linked C-telopeptide of type I collagen (CTX-I) and quantified tartrate-resistant 
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acid phosphatase (TRAP) positive cells in distal femoral sections. Serum levels of CTX-
I showed no changes throughout the evaluated period, and the number of TRAP+ cells 
present on the bone surface was comparable with control 2 weeks following blood loss.  
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Discussion  
In this study, we have established a mouse model of acute blood loss to monitor 
alterations within bone cell lineages following enhanced hematopoiesis. We have 
confirmed previously reported modest effects of acute hemorrhage on total BM 
cellularity, and a consequent increase of extramedullary hematopoiesis [50]. We have 
demonstrated that hemorrhage does not influence BM myeloid precursors nor 
osteoclast precursor cells with a high osteoclastogenic potential. However, at 1 week, 
hematopoiesis significantly promoted the expression of markers of mature osteoclasts 
and osteoblasts, as well as IL-34 and BMP-6. To the best of our knowledge, we are 
among the first to give a comprehensive insight into the extent  that mild hemorrhage, 
as a hematopoietic stress, has on osteoclast differentiation and activity, and 
demonstrated the promotion of osteoblast-coupled osteoclast maturation after 1 week 
of recovery, with unchanged bone resorption up to 2 weeks.   
In our mouse model, we confirmed that blood loss of 10% total blood content is 
sufficient to significantly increase the number of reticulocytes and serum Epo levels, 
which are both good estimators of induced erythropoiesis [43,51]. This increase lead to 
an elevated number of TER119+ cells in BM and spleen as early as 3 days after 
bleeding. In addition, the LSK population, as primitive hematopoietic stem cells, 
expanded both in BM and in spleen, as previously reported by Cheshier et al., [50]. 
Since the hematopoietic potential of HSCs in spleen differs from the BM [52], the 
expansion of LSK cells in spleen may be the result of an observed exaggerated 
extramedullary hematopoiesis, as well as a more frequent cell cycling in spleen [53]. 
The increased LSK population enables sufficient de novo differentiation, both in BM 
and spleen, to replenish lost blood cells. 
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We further investigated whether enhanced hematopoiesis alters a discrete population 
of CD11b+F4/80+, functionally diverse cells. In the BM, macrophages lodged throughout 
the marrow form erythroblastic islands, rings of attached erythroblasts to one or more 
macrophages, which support their proliferation and differentiation to mature blood cells. 
Resident macrophages, ie osteomacs, are important for bone remodeling and the 
maintenance and release of HSCs, as their depletion results in a loss of endosteal OBs 
and consequent HSC mobilization [5]. In spleen, among other roles, macrophages 
control the retention and trafficking of B lymphocytes in the marginal zone [54]. 
Interestingly, the CD11b+F4/80+ population of myeloid precursors in BM was not altered 
until 1 week post-bleeding, and the total number in spleen increased during the entire 
follow-up period. It can only partially be explained by an existence of a reservoir of 
resident and undifferentiated pool of cells ready to be activated to facilitate a prompt 
immune response. In addition, we can speculate that a 10% blood loss due to 
increased demands for blood cells, provided the expansion of myeloid cells in spleen, 
as a recent study revealed that overexpression of erythropoietic regulators causes an 
expansion of myeloid cells in BM and spleen, and disrupts B lymphopoiesis [55].  
Indeed, the hematopoietic response to bleeding affected B-lymphopoiesis, and resulted 
in a reduction in the number of pre-B stage maturation-lymphocytes, most evident after 
3 days of the follow-up period. This is in line with described effects of Epo 
administration in mice [34,56]. Given such diverse and important roles of macrophages 
in BM and spleen hematopoiesis, we can speculate that the hematopoietic 
microenvironment changes the lineage commitment of HSCs in stress conditions by 
promoting myeloid and decreasing lymphoid differentiation, similarly to processes 
during aging [57]. 
Cells of the monocyte-macrophage cell line, the osteoclasts, closely interact with other 
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cells of the BM niche, and it was proposed that bone resorption, as part of bone 
remodeling, provides the space needed for enhanced hematopoiesis, cell maturation, 
and development within the BM cavity [56]. Similarly, several studies indicated a 
positive correlation between enhanced erythropoiesis and osteoclastogenesis [56,58]. 
However, Miyamoto et al., showed an increased HSC mobilization in osteopetrotic mice 
with a mutation in the M-CSF gene, and reduced HSC mobilization in osteoporotic mice 
deficient for osteoprotegerin, a decoy receptor for RANKL [33]. These results may be a 
reflection of different animal models and analysis techniques.  
We analyzed changes of several osteoclast precursor subpopulations. In BM, the 
highest in vitro osteoclastogenic differentiation potential is contained within three 
discrete populations, among which the B220-CD3-NK1.1-CD11b-/lowCD115+CD117+ 
shows the highest potential [19], but we show that enhanced hematopoiesis had little 
effect on this osteoclast subpopulation in BM. Further, phenotypically similar 
subpopulations with high osteoclastogenic potential, expressing CD115 and CD11b, and 
efficiently forming OCLs in vitro conditions [20], in spleen and PBL [20] were slightly 
reduced 3 days post-bleeding. Although described as osteoclast precursors, these 
populations can also generate mature functional macrophages and dendritic cells, 
beside osteoclasts, making inducing properties of BM and bone microenvironment 
crucial in defining the fate of these progenitors. Therefore, we further analyzed 
RANKhighCD115low quiescent osteoclast precursors (QOPs), a population able to 
differentiate into osteoclasts without cell-cycle progression [21,22,59]. In our model, the 
number of QOPs in all analyzed tissues transiently increased during the follow-up week 
with the most prominent increase in spleen after 2 days post-bleeding, indicating 
induced lineage committed differentiation. Although, we focused our study on 
osteoclasts and osteoclast precursors, they largely depend on the interactions with and 
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activity of osteoblasts [23]. We observed an increased BM expression of genes specific 
for osteoblast differentiation and function (OC, Osx, BSP), which is in line with the study 
by Lucas et al., [60]  who have shown increases of the mineral appositional rate, 
osteoblast numbers, and serum concentration of osteogenic growth peptide following an 
acute blood loss in rats. In our model, at 1 week following bleeding, the expression of 
pro-osteoblastic growth factors BMP-6 in BM [61], and cathepsin K, a bone resorbing 
proteinase excreted by mature osteoclasts that mediates the release of HSCs from BM 
[24,26,27], were increased. In addition, IL-34, a newly discovered ligand for c-Fms, 
produced by vascular endothelial cells (mostly in spleen, but also in bone), has been 
proposed as a factor controlling QOP maintenance [40]. Alongside M-CSF it seems to 
be key for homing of QOPs to bone [23]. Supported by a recent study which confirmed 
that committed osteoclast precursors exit the BM, circulate via the bloodstream, and 
enter the bone sites specified for resorption [62], we may speculate of maturation and 
distribution of committed osteoclast precursors, at one week post-bleeding. We 
investigated in vivo activity of osteoclasts by measuring serum levels of C-telopeptide of 
type I collagen (CTX-I), as an indicator of the rate of bone resorption, and determined 
the number of TRAP positive cells adjacent to the bone surface up to 2 weeks.   At 1 
week post-bleeding the maturation of osteoclasts is evident by elevated expressions of 
cathepsin K, IL-34, and osteoblast maturation markers (OC, Osx, BSP) and BMP-6. 
Bone remodeling and the number of TRAP+ cells adjacent to bone were not changed 
up to 2 weeks.    
Several previous studies reported results regarding the effect of bleeding on osteoclast 
differentiation and activity. Johnell et al., [63] showed enhanced number of OCs on rib 
metaphysis on day 3, returning to control levels on day 7, in rats, while Kollet et al., [24] 
presented an elevated number of TRAP+ OC in mice femora peaking at day 7, following 
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blood loss. The study of Moreau et al., [64] reported no change of bone parameters and 
CTX levels in Balb/c mice, demonstrating unchanged OC activity following bleeding, 
although in in vitro conditions the number of TRAP+ OC was enhanced versus control. 
By comparing these results, it is evident that the number of OC and activity depends on 
the murine model, bleeding protocols and techniques used in analysis. Moreover, a 
recent study of Shiozawa et al., [58] showed elevated levels of EPO in mouse sera 
following bleeding, which was confirmed in our study. They have focused their research 
on the effect of EPO administration on bone cells, and reported induced number of OC 
at week 2 and 4, during constant EPO treatment, and showed induced 
osteoclastogenesis which is not accompanied with enhanced osteoclast activity in in 
vitro conditions. Reported results show an elevated number of OC in bone tissue 
following administration of increasing concentration of EPO, and although the authors 
suggest a central role of EPO in bone remodeling following bleeding, it is important to 
stress that such results depend on the study approach. In our model of acute blood 
loss, we measured hematopoietic parameters including EPO levels in sera, which 
showed a peek at day 2, and decreased to homeostatic levels during 1 week, which is 
in contrast to the approach of increased concentrations of EPO administered by 
Shiozawa et al. Further, we alayzed in vitro and in vivo osteoclastogenesis and in vivo 
osteoclast activity, and to our knowledge, this is the first time an emphasis was made on 
discrete osteoclast precursor subpopulations, following bleeding. . .  
In this context, the increased expression of osteoclast and osteoblast differentiation, 
maturation, and function markers, can suggest that after 1 week following blood loss the 
activities of osteoclasts and osteoblasts have reached a new homeostatic level, allowing 
for the establishment of hematopoietic homeostasis and preventing the induction of 
bone resorption.  
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As repetitive blood loss of around 10% total blood amount is typical for full-blood 
donations, future studies on models of chronic critical-amount bleeding are needed to 
evaluate the potential long-term effects on bone remodeling. 
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    Figure Legends 
 
 
Figure 1. Loss of 10% of total blood volume significantly stimulates murine 
hematopoiesis 
 
Animals were subjected to acute hematopoietic stress by drawing 10% of total blood 
volume per mouse with various intervals between bleeding (1 week, 72h, 48h, 24h, 12h) 
and sampling. A) Hematological analysis of the number of reticulocytes and erythrocytes 
in peripheral blood samples. B) Serum erythropoietin concentration measured by ELISA. 
Data are presented as mean±SD. The representative experiment out of three 
independent experiments (3 animals per group) with similar results is presented. C) Flow 
cytometry analysis of bone marrow and spleen cells positive for the erythroid cell marker 
TER119. Bar graphs show absolute number of TER119+ cells in bone marrow and spleen 
presented as mean±SD of three independent experiments. Samples were obtained from 
three mice per group. Group versus control comparisons were calculated using unpaired 
two-tailed Student's test with Bonferroni correction for multiple testing giving the 
significance at p≤0.01. Control (CTRL) denotes nonbled mice. 
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Figure 2. Loss of 10% of total blood volume alters the number of murine LSK and 
myeloid cells 
 
Flow cytometric analysis of freshly isolated bone marrow, spleen and blood samples. A) 
Changes of total cellularity of bone marrow and spleen B) Flow cytometry analysis of Lin-
Sca-1+c-kit+ (LSK) cells from bone marrow and spleen. C) Flow cytometry analysis of 
F4/80+CD11b+ myeloid progenitors in bone marrow, spleen, and blood. 
Samples were obtained from three mice per group. Data are presented as mean±SD of 
three independent experiments. Control (CTRL) denotes nonbled mice. Bar graphs show 
absolute number of bone marrow, spleen and the percentage of the analyzed population 
in blood. 
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Figure 3. Loss of 10% of total blood volume affects murine osteoclast precursor 
population size 
 
Flow cytometric analysis of freshly isolated bone marrow, spleen and blood samples. A) 
Bar graphs show absolute number of bone marrow B220-CD3-NK1.1-CD11b-
/lowCD115+CD117+ and B220-CD3-NK1.1-Gr-1-CD11b+CD115+ cells in spleen and the 
percentage of cells in blood with high potential to generate osteoclast in vitro. B) Bar 
graphs present absolute number of bone marrow, spleen and the percentage of blood of 
CD11b-Gr-1-RANKhighCD115low cells. 
Samples were obtained from three mice per group. Data are presented as mean±SD of 
three independent experiments. Control (CTRL) denotes nonbled mice.  
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Figure 4. Loss of 10% of total blood volume influences murine B-lymphopoiesis 
 
Flow cytometric analysis of freshly isolated bone marrow, spleen and blood samples. Bar 
graphs present absolute number of bone marrow, spleen and the percentage of blood cells of A) 
pre-proB (B220+IgM-CD43+CD19-), B) proB (B220+IgM-CD43+CD19+), and C) preB (B220+IgM-
CD43-CD19+) cells. Samples were obtained from three mice per group. Data are presented as 
mean±SD of three independent experiments. Control (CTRL) denotes nonbled mice.  
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Figure 5. Blood loss promotes expression of murine osteoclast and osteoclast 
specific genes at one week following bleeding 
 
Real-time RT-PCR analysis of the expression of osteoclast and osteoblast differentiation 
genes. A) Expression of cFms (CD115), receptor activator of nuclear factor κB ligand 
(RANK), cathepsin K (CtsK) and interleukin-34 (IL-34) in bone marrow. B) Gene 
expression patterns of Runx2, osterix (Osx), bone sialoprotein (BSP), osteocalcin (OC) 
and bone morphogenetic protein 6 (BMP-6) in bone marrow.   
Data were normalized to β-actin. Fold changes were calculated using ∆∆Ct method, and 
data are presented as mean±SD of PCR reaction technical duplicates. A relative 
quantification was considered significant at minimum two-fold change. Data are 
representative of those obtained for three mice in each group in three independent 
experiments. 
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Figure 6. Reduction of murine in vitro osteoclastogenic potential but not in vivo 
activity following blood loss 
 
Osteoclastogenic potential, number and activity of BM cells in vitro and in vivo. Isolated 
bone marrow cells were cultured in the presence of macrophage colony-stimulating factor 
(M-CSF) for 24h, and nonadherent cells were subsequently plated with receptor activator 
of nuclear factor κB ligand (RANKL) and M-CSF for 3 days to generate tartrate-resistant 
acid phosphatase (TRAP)-positive osteoclast. Multinuclear TRAP+ cells with three or 
more nuclei were counted. Mouse sera were used for quantification of mouse cross-
linked C-telopeptide of type I collagen (CTX-I) and TRAP+ cells were counted in femoral 
sections. A) Number of TRAP+ cells in bone marrow B) Representative light-microscopic 
images of cells expressing TRAP in bone marrow cultures with indicated average number 
of nuclei per osteoclast. Original magnification at 10×. C) Serum levels of CTX-I. D) 
Number of TRAP+ cells per bone perimeter. E) Representative light-microscopic images 
of TRAP stained osteoclasts, indicated with arrowheads, in distal sections of femora of 
untreated mice (left) and bled mice after 2 weeks following bleeding (right). Original 
magnification 20×. 
Data are presented as mean±SD, and are representative of those obtained for three mice 
in each group in three independent experiments. Control (CTRL) denotes nonbled mice. 
Group versus control comparisons were calculated using unpaired two-tailed Student's 
test with Bonferroni correction for multiple testing giving the significance at p≤0.01. 
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